Check for updates

RESEARCH ARTICLE

REVISED **Concordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing [version 2; peer review: 2 approved]**

Chiara De Santi [iD][1], Benson Jacob[2], Patricia Kroich [iD][1], Sean Doyle [iD][2], Rebecca Ward [iD][1], Brian Li[1], Owain Donnelly [iD][2], Amy Dykes [iD][2], Trisha Neelakant[2], David Neary [iD][2], Ross McGuinness [iD][2], Jacqueline Cafferkey[3], Kieran Ryan[4], Veronica Quadu[5], Killian McGrogan[5], Alejandro Garcia Leon[6], Patrick Mallon[6], Fidelma Fitzpatrick [iD][3,7], Hilary Humphreys[3,7], Eoghan De Barra[2,8]*, Steve W. Kerrigan[1]*, Gianpiero L. Cavalleri [iD][1,9]*

[1]School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
[2]Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
[3]Department of Microbiology, Beaumont Hospital, Dublin, Ireland
[4]Department of Surgical Affairs, Royal College of Surgeons in Ireland, Dublin, Ireland
[5]Mercer's Medical Centre, Royal College of Surgeons in Ireland, Dublin, Ireland
[6]Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland
[7]Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland
[8]Department of Infectious Diseases, Beaumont Hospital, Dublin, Ireland
[9]SFI FutureNeuro Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland

* Equal contributors

Abstract

Introduction: Saliva represents a less invasive alternative to nasopharyngeal swab (NPS) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. SalivaDirect is a nucleic acid extraction-free method for detecting SARS-CoV2 in saliva specimens. Studies evaluating the concordance of gold standard NPS and newly developed SalivaDirect protocols are limited. The aim of our study was to assess SalivaDirect as an alternative method for COVID-19 testing.
Methods: Matching NPS and saliva samples were analysed from a cohort of symptomatic (n=127) and asymptomatic (n=181) participants recruited from hospital and university settings, respectively. RNA was extracted from NPS while saliva samples were subjected to the SalivaDirect protocol before RT-qPCR analysis. The presence of SARS-Cov-2 was assessed using *RdRp* and *N1* gene targets in NPS and saliva, respectively.
Results: Overall we observed 94.3% sensitivity (95% CI 87.2-97.5%),

Open Peer Review

Reviewer Status ✓ ✓

	Invited Reviewers	
	1	**2**
version 2 (revision) 15 Oct 2021		
version 1 30 Jul 2021	✓ report	✓ report

1. **Stephanie Russo Perniciaro** [iD], Yale University, New Haven, USA

2. **Mario A. Rodríguez-Pérez** [iD], Centro de

and 95.9% specificity (95% CI 92.4-97.8%) in saliva when compared to matching NPS samples. Analysis of concordance demonstrated 95.5% accuracy overall for the saliva test relative to NPS, and a very high level of agreement (κ coefficient = 0.889, 95% CI 0.833–0.946) between the two sets of specimens. Fourteen of 308 samples were discordant, all from symptomatic patients. Ct values were >30 in 13/14 and >35 in 6/14 samples. No significant difference was found in the Ct values of matching NPS and saliva sample (p=0.860). A highly significant correlation (r = 0.475, p<0.0001) was also found between the Ct values of the concordant positive saliva and NPS specimens.

Conclusions: Use of saliva processed according to the SalivaDirect protocol represents a valid method to detect SARS-CoV-2. Accurate and less invasive saliva screening is an attractive alternative to current testing methods based on NPS and would afford greater capacity to test asymptomatic populations especially in the context of frequent testing.

Keywords
SARS-CoV-2, Saliva, SalivaDirect, Nasopharyngeal swabs, RT-qPCR

Biotecnología Genómica, Reynosa, Mexico

Luis Mario Rodríguez-Martínez, Centro de Biotecnología Genómica, Reynosa, Mexico

Sofia Nohemí Rodríguez-Flores, Unidad de Desarrollo e Investigación en Bioprocesos, Escuela de Ciencias Biológicas, Mexico

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Chiara De Santi (chiaradesanti@rcsi.ie)

Author roles: De Santi C: Conceptualization, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation; **Jacob B**: Project Administration, Resources; **Kroich P**: Investigation, Writing – Original Draft Preparation; **Doyle S**: Project Administration, Resources, Writing – Review & Editing; **Ward R**: Formal Analysis, Visualization, Writing – Original Draft Preparation; **Li B**: Formal Analysis, Resources; **Donnelly O**: Formal Analysis, Investigation, Supervision, Writing – Review & Editing; **Dykes A**: Investigation; **Neelakant T**: Investigation; **Neary D**: Formal Analysis, Investigation; **McGuinness R**: Investigation; **Cafferkey J**: Investigation; **Ryan K**: Funding Acquisition, Project Administration; **Quadu V**: Supervision; **McGrogan K**: Supervision; **Garcia Leon A**: Investigation, Writing – Review & Editing; **Mallon P**: Funding Acquisition, Project Administration, Supervision, Writing – Review & Editing; **Fitzpatrick F**: Conceptualization, Supervision, Writing – Review & Editing; **Humphreys H**: Conceptualization, Supervision, Writing – Review & Editing; **De Barra E**: Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing; **Kerrigan SW**: Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing; **Cavalleri GL**: Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that rapidly spread across the globe in late December 2019 and was declared a pandemic by the World Health Organization (WHO) in March 2020 [press conference WHO 11th March 2020]. Containing the spread of SARS-CoV-2 has been a significant challenge worldwide mainly because both asymptomatic and symptomatic individuals can transmit the virus (Huff & Singh, 2020). A key approach to limiting cross-infection is robust testing and contact tracing. Currently, the gold standard for diagnosis is nucleic acid detection by reverse transcription quantitative PCR (RT-qPCR) (Adhikari *et al.*, 2020). Nasopharyngeal swabs (NPS) were initially adopted as the preferred sampling procedure for SARS-CoV-2, due to established diagnostic practices for other respiratory infections (Li *et al.*, 2013; Lieberman *et al.*, 2009). However, NPS are invasive and may induce coughing and sneezing, increasing the risk of transmission to healthcare professionals (HCP) conducting the procedure (Kim *et al.*, 2016). NPS discomfort can also be a barrier to repeated, frequent testing as swabbing can induce effects that can last up to 24 hours post procedure including epistaxis, headaches, earaches and rhinorrhea (Gupta *et al.*, 2021).

Testing for SARS-CoV-2 in saliva mitigates many of the challenges associated with NPS sampling (Tan *et al.*, 2021; Vaz *et al.*, 2020; Wyllie *et al.*, 2020). Although various different protocols for SARS-CoV-2 testing in saliva have been proposed, including colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) and lateral flow assays (Faustini *et al.*, 2020; Lalli *et al.*, 2021), RT-qPCR is the most common used modality (Caulley *et al.*, 2021; Migueres *et al.*, 2020; Teo *et al.*, 2021) with a reported sensitivity between ~ 69 to 100% (Azzi *et al.*, 2020; Kojima *et al.*, 2020; Pasomsub *et al.*, 2021; Skolimowska *et al.*, 2020; To *et al.*, 2020).

SalivaDirect is a nucleic acid extraction-free, cost effective and reliable method for detecting SARS-CoV2 which has been authorised for use by the FDA (Vogels *et al.*, 2021, FDA press release 15th August 2020). Using SalivaDirect, specimens can be self-collected in a sterile sample tube without a viral transport medium. Proteinase K addition and a short heat-treatment step precede RT-qPCR analysis (Vogels *et al.*, 2021). Initial studies using SalivaDirect reported a significant positive agreement (94%) between paired saliva and NPS samples obtained from a hospital cohort of 37 asymptomatic HCP and 30 COVID-19-positive inpatients (Vogels *et al.*, 2021). In another study, matched saliva and NPS samples obtained from 30 individuals with COVID-19 illustrated a 88.2% concordance when using the SalivaDirect protocol (Rodríguez Flores *et al.*, 2021).

Data comparing the concordance of 'gold standard' NPS and the SalivaDirect protocol for ongoing testing as part of an infection prevention and control programme are limited. In the present study, we set out to compare matching NPS and extraction-free saliva samples for detection of SARS-CoV-2 viral RNA via RT-qPCR, to assess the suitability of saliva as an alternative specimen for COVID-19 testing. We studied two key demographics – asymptomatic university students and hospital inpatients admitted with respiratory symptoms due to COVID-19 related illnesses.

Methods

Ethical considerations

This study was approved by the Ethics Committee of Royal College of Surgeons in Ireland (RCSI) (study code: REC202010011) and the National Research Ethics Committee for COVID-19 (20-NREC-COV-056). All subjects involved in this study provided written informed consent.

Sample collection

Research participants were recruited at two sites; a symptomatic patient cohort (n=127) was assembled at Beaumont Hospital, Dublin, Ireland and an asymptomatic 'student' cohort (n=181) at RCSI University of Medicine and Health Sciences, Dublin, Ireland. Recruitment took place during the period from November 2020 to March 2021 for the symptomatic population and in December 2020 and January 2021 for the asymptomatic student cohort.

Symptomatic individuals were inpatients at Beaumont Hospital who tested positive for SARS-CoV-2 on NPS-based diagnostic admission testing, carried out in the hospital's clinical microbiology laboratory (using either the CerTest Biotec VIASURE SARS-CoV-2 real time PCR detection kit or Cepheid Xpert Xpress SARS-CoV-2). Patients were recruited to the research study post admission to hospital. Individuals in the symptomatic arm provided a research NPS sample, (collected by a trained professional), and a saliva sample (collected by passive drooling). The research NPS and saliva were collected on the same day. Asymptomatic students were recruited via an in-house screening programme at RCSI. NPS samples

were collected by a trained professional with a saliva sample collected by passive drooling immediately afterwards. In both cohorts, exclusion criteria for participation to the study were any of the following activities conducted in the half hour prior to saliva sample collection: smoking, drinking any liquids, food, nasal sprays, tooth brushing and/or mouth washing. We set these as exclusion criteria as these activities might leave residues in the saliva (thereby influencing the samples quality of the sample and associated handling in the laboratory) or affect the samples viral load in the sample (Eduardo *et al.*, 2021; Seneviratne *et al.*, 2021).

NPS sample processing

NPS from the symptomatic cohort were placed in 2 ml of Viral Transport Media and sent to the CEPHR Laboratory using a biomedical courier. Samples were aliquoted into 2 ml cryovials and stored at -80°C until further use. Using 250 µl of the biobanked NPS, RNA was extracted using the automated platform for nucleic acid extraction EX3600 (Liferiver Biotech, Shanghai, China) according to manufacturer's instructions, with a nucleic acid elution volume of 60 µl. Following RNA extraction, samples underwent RT-qPCR for SARS-CoV-2 with primers directed against the RNA-dependent RNA polymerase (*RdRp*) region of the viral genome, using the COVID-19 Genesig Real-Time PCR assay (Primerdesign Ltd, Hampshire, United Kingdom) on The LightCycler 480 PCR platform (Roche Diagnostics, Basel, Switzerland) with the following thermocycling conditions: 10 min 55°C, 2 min 95°C, 45 cycles of 10 sec 95°C/60 sec 60°C. Each run included a SARS-CoV-2 positive control (RNA), internal control, no-template control and a positive control of extraction (RNA from SARS-CoV-2 virus - 2019-nCoV/Italy-INMI1). Samples with quantification cycle (Cq) values below 40 cycles were defined as SARS-CoV-2-detected.

NPS from the asymptomatic cohort were processed in the COVID-19 Testing Lab at RCSI. RNA extraction for NPS samples was performed using a MagMax Viral/Pathogen II Nucleic Acid Isolation Kit (ThermoFisher Scientific), as per manufacturers' instructions on a KingFisher Flex Purification system (model 5400630, ThermoFisher Scientific) instrument using 200 µL of NPS sample input. RT-qPCR followed the Centers for Disease Control and Prevention (CDC) protocol (Lu *et al.*, 2020). Briefly, amplification of the SARS-CoV-2 nucleocapsid gene (*N1* and *N2)* and internal control (*RP*) was performed using TaqPath 1-Step RT-qPCR Master Mix (4x, ThermoFisher Scientific) with the following sets of primers and probes: N1_F primer 5′- GACCCCAAAATCAGCGAAAT -3′ (500nM), N1_R primer 5′- TCTGGTTACTGCCAGTTGAATCTG -3′ (500nM), and N1_probe 5′-FAM-ACCCCGCAT-TACGTTTGGTGGACC -BHQ1-3′ (125nM); N2_F primer 5′- TTACAAACATTGGCCGCAAA -3′ (500nM), N2_R primer 5′- GCGCGACATTCCGAAGAA -3′ (500nM), and N2_probe 5′-Cy3- ACAATTTGCCCCCAGCGCTTCAG -BHQ1-3′ (125nM); RP_F primer 5′- AGATTTGGACCTGCGAGCG -3′ (500nM), RP_R primer 5′- GAGCGGCTGTCTCCACAAGT -3′ (500nM), and RP_probe 5′-Cy5- TTCTGACCTGAAG-GCTCTGCGCG -BHQ1-3′ (125nM). The TaqPath RT-qPCR Master Mix (15 µL) was added to 5 µL of the RNA extracted

from each NPS sample and run on a QuantStudio 7 (ThermoFisher Scientific) Pro Real-Time PCR with the following thermocycling conditions: 2 min 25°C, 15 min 50°C, 2 min 95°C and 45 cycles of 3 sec 95°C/30 sec 55°C. Cycle threshold (Ct) values lower than 40 was interpreted as detection of the gene and viral status of the clinical samples was called as per CDC recommendation (Lu *et al.*, 2020).

Saliva sample processing

All saliva specimens (*i.e.* from both the symptomatic and asymptomatic cohorts) were processed in the COVID-19 Testing Laboratory at RCSI using the SalivaDirect protocol (Vogels *et al.*, 2021). Briefly, 50 µl of each saliva sample was added to 2.5 µl of proteinase K (50 mg/ml, ThermoFisher Scientific), vortexed and incubated at 95°C for 5 minutes to ensure inactivation of the virus. The handling of the saliva samples (which were of a thick consistency) was performed with particular attention in order to avoid between-samples contamination. RT-qPCR amplification was performed using TaqPath 1-Step RT-qPCR Master Mix (4x, ThermoFisher Scientific), and the CDC *N1* and *RP* sets of primers and probes as per SalivaDirect protocol at the following concentrations: N1_F primer (400nM), N1_R primer (400nM), and N1_probe (200nM); RP_F primer (150nM), RP_R primer (150nM), and RP_probe (200nM). The TaqPath RT-qPCR Master Mix (15 µL) was added to 5 µL of the "extraction-free" saliva sample and run on a QuantStudio 7 Pro Real-Time PCR with the following thermocycling conditions: 10 min 52°C, 2 min 95°C and 45 cycles of 10 sec 95°C/30 sec 55°C. Ct values lower than 40 were interpreted as detection of the gene and viral status was called as per SalivaDirect recommendation (Vogels *et al.*, 2021).

RNA extraction from saliva and SARS-CoV-2 detection using TaqPath COVID-19 CE-IVD RT-PCR Kit

In some cases, i.e. when the saliva and NPS testing results were not concordant, saliva samples were extracted using the MagMax Viral/Pathogen II Nucleic Acid Isolation Kit (ThermoFisher Scientific) following the protocol described above for NPS processing. This was a quality control step introduced to reduce the risk of false positive or negative results from saliva processed according to SalivaDirect protocol. RT-qPCR amplification of the SARS-CoV-2 *ORF1* gene, *N* gene and *S* gene was performed using TaqPath 1-Step Multiplex Master Mix (No ROX) (4X) and the TaqPath COVID-19 CE-IVD RT-PCR Kit as per manufacturers' instructions. Briefly, 15 µL of the prepared mix were added to 10 µL of the RNA extracted from each saliva sample and run on a QuantStudio 7 Pro Real-Time PCR with the following thermocycling conditions: 2 min 25°C, 10 min 53°C, 2 min 95°C, and 40 cycles of 3 sec 95°C/30 sec 60°C. Ct values lower than 37 were interpreted as indicating the expression of that gene and viral status was called as per TaqPath COVID-19 CE-IVD RT-PCR Kit manufacturers' instructions.

Statistical analyses

All statistical analyses were performed using GraphPad PRISM version 8.0.0 (GraphPad Software, San Diego, CA, USA). Sensitivity, specificity and 95% confidence intervals

(CI) were calculated to assess diagnostic performance. Agreement between the NPS and saliva specimens for the virus detection ability was also assessed using Cohen's Kappa (κ coefficient). Paired *t*-tests were used to compare the Ct values between NPS and saliva. Correlation between NPS and saliva Ct values were quantified using the Pearson correlation coefficient (Pearson *r*). All *p*-values were two-sided and *p* <0.05 was considered significant.

Results

A total of 308 individuals, 181 asymptomatic students and 127 symptomatic patients, were included in this study (Table 1).

We first tested the correlation between NPS and saliva testing results in the symptomatic cohort. SARS-CoV-2 was detected in 86 of 127 patient NPS, while it was undetected in 41. Saliva testing in the same cohort indicated that 90 patients tested positive for SARS-CoV-2, while 37 tested negative. The sensitivity of saliva compared to NPS was 94.2% (95% CI 87.1-97.4%), while the specificity was 78.1% (95% CI 63.3-88%) in our symptomatic cohort.

We next tested the correlation between NPS and saliva in the asymptomatic cohort. Of 181 students, one tested positive both in NPS and saliva samples, while 180 tested negative in both. Sensitivity (95% CI 5-100%) and specificity (95% CI 97.9-100%) were therefore both 100% in this cohort.

The overall concordance between NPS and saliva testing is shown in Table 2. In the combined cohort, the sensitivity of saliva compared to NPS was 94.3% (95% CI 87.2-97.5%), while the specificity was 95.9% (95% CI 92.4-97.8%). Analysis of the concordance between the NPS and saliva

specimens demonstrated an overall 95.5% accuracy for the saliva test relative to NPS and a very high level of agreement (κ coefficient = 0.889, 95% CI 0.833–0.946) between the two specimens. Nonetheless, we found 14 discordant samples between saliva and NPS. SARS-CoV-2 was detected in nine saliva samples but not detected in their matched NPS. On the other hand, viral RNA was not detected in five saliva samples but detected in the matched NPS. All 14 discordant samples belonged to the symptomatic hospitalised cohort. Ct values were >30 in 13/14 of these discordant samples and >35 in 6/14 samples.

To further explore the discordant results, we extracted RNA from the 14 discordant saliva samples and retested the samples with the TaqPath COVID-19 CE-IVD RT-PCR kit. SARS-CoV-2 viral RNA detection was confirmed in 7/9 'false positive' saliva samples, indicating these were actually true positives which the NPS test failed to detect. The remaining two saliva samples in which SARS-CoV-2 was undetected had Ct values ≥35 using the SalivaDirect protocol. All five 'false negative' also tested negative using the TaqPath protocol, indicating that in this case saliva testing failed to detect the virus which was instead detected by NPS testing. The *RdRp* Ct values from NPS from these samples were >30 using the Genesig Real-Time PCR assay.

We next compared the Ct values of the concordant positive saliva and NPS samples (Figure 1A) in the symptomatic cohort. *N1* Ct values were reported for saliva samples according to SalivaDirect protocol, and *RdRp* Ct values for the NPS were reported, as it is the target gene of the Genesig Real-Time PCR assay. The overall mean and standard deviation (SD) Ct value for the positive NPS specimens and saliva

Table 1. Demographic and clinical characteristics of the symptomatic (n=127) and asymptomatic (n=181) cohorts. For the symptomatic patients, we report the maximum COVID-19 disease severity (as per WHO guidelines) reached during their hospital stay.

		Hospitalised patients (n=127)	Students (n=181)
Sex (%)	Male	44.9	45.4
	Female	37.8	52.4
	Unknown	17.3	2.2
Age (years)	Median (IQR$^\$$)	68 (26)	24 (3)
Clinical Phenotype (%)		Mild: 31.5	Asymptomatic: 100
		Moderate: 20.5	
		Severe: 18.9	
		Critical*: 9.4	
		Unknown: 19.7	

$^\$$Interquantile Range; *Critical COVID-19 severity score included both sepsis (n=3) and acute respiratory distress syndrome (ARDS) (n=9).

samples was 26.36 (SD 7.03) and 26.49 (SD 6.04), respectively. The difference in mean Ct values (0.132) was not statistically significant (p=0.860). We also found a highly significant correlation between the Ct values of the positive saliva and NPS specimens (Pearson r = 0.475, p<0.0001, Figure 1B).

Finally, we compared NPS and saliva test results obtained from the hospitalised symptomatic patients (127 individuals) with the results from their initial positive diagnostic SARS-CoV-2 swab, which was performed on admission to hospital. The average time between the initial diagnostic NPS and the paired (same day) research saliva and NPS was 4.73 days (95% CI 4.05-5.42) post initial diagnosis. As expected, the positive agreement of NPS and saliva testing decreased with time, but a similar pattern for saliva and NPS is notable (see Figure 2).

Discussion

Use of saliva to detect SARS-CoV-2 represents a valid and accurate alternative to NPS sampling. Our results indicate a 94.3% sensitivity and 95.9% specificity of saliva when compared to a matching NPS taken on the same day in a combined cohort of symptomatic and asymptomatic individuals. Our results are consistent with the original publication of the SalivaDirect method, where the positive agreement was 94% in the hospitalised cohort, and sensitivity and specificity of saliva versus NPS in 3779 asymptomatic individuals were 89.5% and >99.9%, respectively (Vogels *et al.*, 2021). A separate study reported a sensitivity of 88.2% of saliva samples assessed with SalivaDirect when compared to matching NPS samples taken from 30 COVID-19-positive individuals (Rodríguez Flores *et al.*, 2021).

In samples where the virus was detected, we observed a strong correlation between viral gene Ct values across NPS and saliva

Table 2. Diagnostic performance of SalivaDirect protocol compared to the gold standard NPS testing in a symptomatic (n=127) and asymptomatic (n=181) cohorts.

		Nasopharyngeal swab	
		Positive	**Negative**
Salivadirect – Saliva	Positive	82	9
	Negative	5	212
Total		87	221
Positive agreement = 94.3 % (95 % CI 87.2-97.5 %)			
Negative agreement = 95.9 % (95 % CI 92.4-97.8 %)			

Figure 1. Comparison of Ct values from concordant positive saliva and NPS samples from the symptomatic cohort (n=81). (**A**) The mean Ct values for saliva specimens are not significantly different than the mean for NPS specimens. The lines indicate samples from the same patient. (**B**) Correlation of Ct values between saliva (*N1*) and NPS (*RdRp*) PCR. The scatter plot shows the comparison of Ct values between the two methods.

Figure 2. Percentage of sensitivity of saliva and repeat NPS in the symptomatic cohort (n=127). X axis: the delay (in days) between the positive NPS on hospital admission and the collection of the matching saliva and NPS sample. Matching NPS/saliva samples taken > 7 days post admission were pooled and reported as '>7' (average of 11.53 days, 95% CI 10.02-13.03).

samples, consistent with recent reports (Braz-Silva *et al.*, 2020; Mahmoud *et al.*, 2021). Saliva-positive samples often differ from NPS in terms of Ct values/viral load (Braz-Silva *et al.*, 2021; Skolimowska *et al.*, 2020; Wyllie *et al.*, 2020), however in our hands NPS and saliva samples showed similar Ct values, possibly due to the fact that we tested for different viral genes for NPS (*RdRp*) and saliva (*N1*).

Although we found an overall accuracy of 95.5%, 14 samples from the symptomatic cohort were discordant between matching NPS and saliva samples, with five individuals testing positive by NPS only and nine by saliva only. The majority of these samples showed Ct values (of either *RdRp* for NPS or *N1* for saliva) over 30, suggesting that a higher discordance between NPS and saliva testing results could be observed for high Ct values, as reported before (Kandel *et al.*, 2020). When we extracted RNA from the 14 discordant saliva samples and tested them using an alternative PCR protocol, we found two 'false positives' in saliva. This confirmatory step in case of high Ct values from the SalivaDirect protocol could therefore be helpful to avoid false positives, which are proportionally greater in low prevalence settings (Basile *et al.*, 2020; Healy *et al.*, 2021).

In the hospitalised symptomatic cohort, we assessed the positivity rate in NPS, and saliva samples taken a variable amount of time after the first diagnosis. As expected, the positive agreement between the first diagnosis and the saliva or repeat NPS decreased over time, reflecting recovery and viral clearance. These findings are consistent with other longitudinal studies of COVID-19 testing (Smith *et al.*, 2021; Wyllie *et al.*, 2020). However, our results are the first to show that the drop in performance is consistent across saliva and NPS, thereby showing once again that the SalivaDirect accuracy is very similar to the gold-standard RT-qPCR from NPS.

Limitations of the current study include the presence of only one positive in the asymptomatic population which limits

the value of the sensitivity calculation in that cohort. In addition, a more closely matched control group would have been beneficial in this study, as samples from a healthy student population were compared to the symptomatic hospitalised cohort. Lastly, the use of Ct values shows a trend of the viral load but does not allow exact quantification of viral copies/ml due to the absence of a standard curve included in the RT-qPCR analyses.

Overall, although the sensitivity and specificity are slightly lower, this work suggests that the SalivaDirect protocol represents a valid alternative to NPS. Other diagnostic assays are available including lateral flow antigen tests (LFAT). However, a pilot study applying LFAT in an asymptomatic population in the UK indicated a sensitivity of only ~49% when compared to gold standard NPS testing (Wise, 2020). More recent studies have reported sensitivities for rapid antigen testing compared to NPS-based molecular testing (i.e. RT-qPCR) of ~93% (Fernandez-Montero *et al.*, 2021; Krüger *et al.*, 2021; Van der Moeren *et al.*, 2021) in the presence of low Ct values/high viral load, however these values dropped when including high Ct values/low viral load (71.4%, 79.8% and 82.2% in the three works, respectively). In our hands SalivaDirect sensitivity compared to NPS was retained for high Ct values by showing a sensitivity of 100% for Ct values lower than 30 and 94.3% overall. Most importantly, rapid antigen tests currently in use still require NPS as the sampling method, which is widely perceived as uncomfortable and could be a barrier for repeated testing. On the other hand, SalivaDirect employs saliva as input, which is less invasive and hence a more acceptable sampling method compared to NPS. (Goldfarb *et al.*, 2021; Kinloch *et al.*, 2020) and whose collection does not require direct interaction between HCP and individuals. This offers several advantages, decreasing the potential for cross-infection as well as alleviating testing bottlenecks by decreasing the need for qualified HCP, personal protective equipment, and swab supply (Wyllie *et al.*, 2020). Saliva can be self-collected, although individuals should be instructed in proper use of the self-collection tube, including its decontamination after saliva collection. These advantages are particularly relevant in the context of a surveillance programme where compliance rates play a crucial role in the long-term success of the screening initiative and individuals would benefit from a less invasive and accurate sampling method, easier to collect in a serial manner.

Data availability

DRYAD: Concordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing, https://doi.org/10.5061/dryad.ksn02v74n (De Santi, 2021)

This project contains the following underlying data:

1. Ct_values_for_matched_NPS_and_saliva_samples_ (asymptomatic_cohort).xlsx.This table shows the Ct values of *N1* (both for NPS and saliva) in the samples belonging to the asymptomatic cohort (n=181 students).

2. Ct_values_for_matched_NPS_and_saliva_samples_ (symptomatic_cohort).xlsx. This table shows the Ct values of *RdRp* (NPS) and *N1* (saliva) in the samples

belonging to the symptomatic cohort (n=127 hospitalised symptomatic individuals).

Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Acknowledgements

We are grateful to the students at the Royal College of Surgeons in Ireland and inpatients at Beaumont hospital who shared their samples and data for this study. We would like to thank our colleagues Jennifer Dowling, Richard Carroll, Stephanie Annett and Sudipto Das (School of Pharmacy and Biomolecular Sciences, RCSI) for their advice and support in setting up the COVID-19 Testing Laboratory at RCSI. We also thank Prof Samuel McConkey (Department of International Health and Tropical Medicine, RCSI) for his input in the discussion around this manuscript. Finally, we thank Zoe Yandle and Jonathan Dean (National Virus Reference Laboratory) and Prof Jonathan Ball (University of Nottingham) for their advices about setting up saliva testing at RCSI.

References

Adhikari SP, Meng S, Wu YJ, *et al.*: **Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review.** *Infect Dis Poverty.* 2020; **9**(1): 29.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Azzi L, Carcano G, Gianfagna F, *et al.*: **Saliva is a reliable tool to detect SARS-CoV-2.** *J Infect.* 2020; **81**(1): e45–e50.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Basile K, Maddocks S, Kok J, *et al.*: **Accuracy amidst ambiguity: false positive SARS-CoV-2 nucleic acid tests when COVID-19 prevalence is low.** *Pathology.* 2020; **52**(7): 809–811.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Braz-Silva PH, Mamana AC, Romano CM, *et al.*: **Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19.** *J Oral Microbiol.* 2020; **13**(1): 1858002.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Caulley L, Corsten M, Eapen L, *et al.*: **Salivary Detection of COVID-19.** *Ann Intern Med.* 2021; **174**(1): 131–133.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

De Santi C: **Concordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing**. Dryad, Dataset, 2021.
http://www.doi.org/10.5061/dryad.ksn02v74n

Eduardo FP, Corrêa L, Heller D, *et al.*: **Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial.** *Heliyon.* 2021; **7**(6): e07346.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Faustini SE, Jossi SE, Perez-Toledo M, *et al.*: **Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection.** *medRxiv.* 2020; 2020.06.16.20133025.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Fernandez-Montero A, Argemi J, Rodríguez JA, *et al.*: **Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in asymptomatic populations. Sensitivity, specificity and predictive values.** *EClinicalMedicine.* 2021; **37**: 100954.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Goldfarb DM, Tilley P, Al-Rawahi GN, *et al.*: **Self-Collected Saline Gargle Samples as an Alternative to Health Care Worker-Collected Nasopharyngeal Swabs for COVID-19 Diagnosis in Outpatients.** *J Clin Microbiol.* 2021; **9**(4): e02427–20.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Gupta K, Bellino PM, Charness ME: **Adverse effects of nasopharyngeal swabs: Three-dimensional printed versus commercial swabs.** *Infect Control Hosp Epidemiol.* 2021; **42**(5): 641–642.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Healy B, Khan A, Metezai H, *et al.*: **The impact of false positive COVID-19 results in an area of low prevalence.** *Clin Med (Lond).* 2021; **21**(1): e54–e56.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Huff HV, Singh A: **Asymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies.** *Clin Infect Dis.* 2020; **71**(10): 2752–2756.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Kandel C, Zheng J, McCready J, *et al.*: **Detection of SARS-CoV-2 from Saliva as Compared to Nasopharyngeal Swabs in Outpatients.** *Viruses.* 2020; **12**(11): 1314.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Kim YG, Yun SG, Kim MY, *et al.*: **Comparison between Saliva and Nasopharyngeal Swab Specimens for Detection of Respiratory Viruses by Multiplex Reverse Transcription-PCR.** *J Clin Microbiol.* 2016; **55**(1): 226–233.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Kinloch NN, Shahid A, Ritchie G, *et al.*: **Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics.** *Open Forum Infect Dis.* 2020; **7**(11): ofaa488.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Kojima N, Turner F, Slepnev V, *et al.*: **Self-Collected Oral Fluid and Nasal Swab Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal Swab Specimens for the Detection of SARS-CoV-2.** *Clin Infect Dis.* 2020; ciaa1589.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Krüger LJ, Klein JAF, Tobian F, *et al.*: **Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for *SARS-CoV-2*.** *Infection.* 2021; 1–12.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Lalli MA, Langmade JS, Chen X, *et al.*: **Rapid and Extraction-Free Detection of SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated Isothermal Amplification.** *Clin Chem.* 2021; **67**(2): 415–424.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Li L, Chen QY, Li YY, *et al.*: **Comparison among nasopharyngeal swab, nasal wash, and oropharyngeal swab for respiratory virus detection in adults with acute pharyngitis.** *BMC Infect Dis.* 2013; **13**: 281.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Lieberman D, Lieberman D, Shimoni A, *et al.*: **Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling.** *J Clin Microbiol.* 2009; **47**(11): 3439–3443.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Lu X, Wang L, Sakthivel SK, *et al.*: **US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2.** *Emerg Infect Dis.* 2020; **26**(8): 1654–1665.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Mahmoud SA, Ganesan S, Ibrahim E, *et al.*: **Evaluation of RNA extraction free method for detection of SARS-COV-2 in salivary samples for mass screening for COVID-19.** *Biomed Res Int.* 2021; **2021**: 5568350.
PubMed Abstract | **Publisher Full Text**

Migueres M, Mengelle C, Dimeglio C, *et al.*: **Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers.** *J Clin Virol.* 2020; **130**: 104580.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Pasomsub E, Watcharananan SP, Boonyawat K, *et al.*: **Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study.** *Clin Microbiol Infect.* 2021; **27**(2): 285.e1–285.e4.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Rodríguez Flores SN, Rodríguez-Martínez LM, Reyes-Berrones BL, *et al.*: **Comparison Between a Standard and SalivaDirect RNA Extraction Protocol for Molecular Diagnosis of SARS-CoV-2 Using Nasopharyngeal Swab and Saliva Clinical Samples.** *Front Bioeng Biotechnol.* 2021; **9**: 638902.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Seneviratne CJ, Balan P, Ko KKK, *et al.*: **Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore.** *Infection.* 2021; **49**(2): 305–311.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Skolimowska K, Rayment M, Jones R, *et al.*: **Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence.** *Clin Microbiol Infect.* 2020; **26**(12): 1711–1713.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Smith RL, Gibson LL, Martinez PP, *et al.*: **Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infection.** *MedRxiv [PREPRINT].* 2021.
Publisher Full Text

Tan SH, Allicock O, Armstrong-Hough M, *et al.*: **Saliva as a gold-standard sample for SARS-CoV-2 detection.** *Lancet Respir Med.* 2021; **9**(6): 562–564.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Teo AKJ, Choudhury Y, Tan IB, *et al.*: **Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection.** *Sci Rep.* 2021; **11**(1): 3134.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

To KKW, Tsang OTY, Yip CCY, *et al.*: **Consistent Detection of 2019 Novel Coronavirus in Saliva.** *Clin Infect Dis.* 2020; **71**(15): 841–843.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Van der Moeren N, Zwart VF, Lodder EB, *et al.*: **Evaluation of the test accuracy of a SARS-CoV-2 rapid antigen test in symptomatic community dwelling individuals in the Netherlands.** *PLoS One.* 2021; **16**(5): e0250886.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Vaz SN, de Santana DS, Netto EM, *et al.*: **Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection.** *Brazilian J Infect Dis.* 2020; **24**(5): 422–427.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Vogels CBF, Watkins AE, Harden CA, *et al.*: **SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity.** *Med (N Y).* 2021; **2**(3): 263–280.e6.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Wise J: **Covid-19: Lateral flow tests miss over half of cases, Liverpool pilot data show.** *BMJ.* 2020; **371**: m4848.
PubMed Abstract | **Publisher Full Text**

Wyllie AL, Fournier J, Casanovas-Massana A, *et al.*: **Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.** *N Engl J Med.* 2020; **383**(13): 1283–1286.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

Open Peer Review

Current Peer Review Status: ✅ ✅

Version 1

Reviewer Report 31 August 2021

✅ **Mario A. Rodríguez-Pérez** ⓘD

Instituto Politécnico Nacional. Centro de Biotecnología Genómica. Reynosa, México., Centro de Biotecnología Genómica, Reynosa, Mexico

Luis Mario Rodríguez-Martínez

Instituto Politécnico Nacional, Centro de Biotecnología Genómica, Reynosa, Mexico

Sofia Nohemí Rodríguez-Flores

Instituto Politécnico Nacional, Unidad de Desarrollo e Investigación en Bioprocesos, Escuela de Ciencias Biológicas, Ciudad de México, Mexico

General comments

The present study compares NPS and Saliva as a COVID-19 sample source. The study included the diagnosis of a "cohort" of 127 symptomatic participants and 181 asymptomatic participants with COVID-19; however, it is not clear how many samples were taken per patient, the date (day), and the viral loads expressed as CTs. Figure 2 depicts that the sampling was conducted several times; however, in fragments of the writing text it appears that only one sample was taken per participant; thus, it would not be a cohort as it is from a longitudinal study. Instead, this study would be cross-sectional since the sample was taken per participant in a single moment. The authors should clarify which is correct.

The number of samples evaluated of 308 is enough to widely support the findings: 94.3% sensitivity and specificity of 95.9%.

In this comparison study, the authors have evaluated two systems: Firstly, the CDC protocols using RT-qPCR with N1, N2 genes, and RP for SARS-CoV-2; Secondly, if the sample was not concordant in its result, it was evaluated with the TaqPath COVID-19 CE-IVD RT-PCR kit, which uses the ORF, N, and S genes as a confirmatory test. Finally, this implied a robust and reliable result; this was done for the 14 non concordant (discordant) samples found.

Particular comments and edits

Methods

Saliva sample processing

"Briefly, 50 µl of each saliva sample was added to 2.5 µl of proteinase K"- Mention the concentration or units of proteinase K added and Brand.

Mention about RT-qPCR cycle changes with NPS and saliva.

"RNA extraction from saliva and SarS-CoV-2 detection using TaqPath COVID-19 CE-IVD RT-PCR Kit". Correct in subtitle "SarS-CoV-2" to "SARS-CoV-2"

Results

"Sensitivity (95% CI 5-100%) and specificity (95% CI 97.9-100%) were, therefore, both 100% in this cohort."

95%-CIs surrounding the point estimator of sensitivity is too wide (5-100%). Re-calculate values or clarify.

Table 2 could be improved, for example, place 3 columns indicating detection method, positive, and negative. Transfer results of NPS into a row.

Figure 2 in the Y-axis named as "Sensitivity" correct to "Sensitivity (%).

In the Figure´s legend, instead of "Sensitivity (in%) ..." correct to "Percentage of sensitivity ..."

Discussion

Discuss what it may imply that by testing saliva this does not meet the established requirements (smoking, drinking fluids, etc.)

It should be compared to currently used methods for rapid detection showing over 90% sensitivity. Why use SalivaDirect and not those?

Did the authors notice any disadvantages of using the SalivaDirect? If so, discuss it.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 01 Oct 2021

Chiara De Santi, Royal College of Surgeons in Ireland, Dublin, Ireland

We thank the reviewers for their summary, comments and suggestions. Please find a point-by-point answer to the reviewers' queries below:

General comments
The present study compares NPS and Saliva as a COVID-19 sample source. The study included the diagnosis of a "cohort" of 127 symptomatic participants and 181 asymptomatic participants with COVID-19; however, it is not clear how many samples were taken per patient, the date (day), and the viral loads expressed as CTs. Figure 2 depicts that the sampling was conducted several times; however, in fragments of the writing text it appears that only one sample was taken per participant; thus, it would not be a cohort as it is from a longitudinal study. Instead, this study would be cross-sectional since the sample was taken per participant in a single moment. The authors should clarify which is correct.
The number of samples evaluated of 308 is enough to widely support the findings: 94.3% sensitivity and specificity of 95.9%.
In this comparison study, the authors have evaluated two systems: Firstly, the CDC protocols using RT-qPCR with N1, N2 genes, and RP for SARS-CoV-2; Secondly, if the sample was not concordant in its result, it was evaluated with the TaqPath COVID-19 CE-IVD RT-PCR kit, which uses the ORF, N, and S genes as a confirmatory test. Finally, this implied a robust and reliable result; this was done for the 14 non concordant (discordant) samples found.
Answer: We thank the reviewer for their summary and comments. In response to the comment on the longitudinal vs cross-sectional study definition, we have now added explanatory sentences both in the methods and results section. Briefly, the symptomatic cohort consisted of inpatients who provided a first NPS sample on admission to hospital (tested in the hospital laboratories). They were recruited to the study while in hospital and provided a second NPS sample on the same day as the saliva sample, both available for research purposes/the current study. Therefore, we consider this section of the work a

longitudinal study. However, the asymptomatic cohort (students) only provided one same day NPS/saliva sample during their appointment as per routine in-house screening at our University (RCSI).

Methods

Saliva sample processing
"Briefly, 50 μl of each saliva sample was added to 2.5 μl of proteinase K"- Mention the concentration or units of proteinase K added and Brand.
Answer: This detail has now been added to the methods section text.

Mention about RT-qPCR cycle changes with NPS and saliva.
Answer: The comparison between Cts from concordant NPS and saliva samples (for the symptomatic cohort) is addressed in the results section ("We next compared the Ct values of the concordant positive saliva and NPS samples (Figure 1A) in the symptomatic cohort...") and shown in Figure 1. Although we did observe strong correlation between the Ct values in NSP and saliva as expected from the literature, we did not see significant differences in Ct count as other relevant publications have reported. This point has not been added to the discussion section, where we mention that it should be noted that we tested for different viral genes for NPS (*RdRp*) and saliva (*N1*).

"RNA extraction from saliva and SarS-CoV-2 detection using TaqPath COVID-19 CE-IVD RT-PCR Kit". Correct in subtitle "SarS-CoV-2" to "SARS-CoV-2"
Answer: This has now been changed in the method section.

Results

"Sensitivity (95% CI 5-100%) and specificity (95% CI 97.9-100%) were, therefore, both 100% in this cohort." 95%-CIs surrounding the point estimator of sensitivity is too wide (5-100%). Re-calculate values or
clarify.
Answer: The 95%-CIs surrounding the sensitivity (*CI 5-100%)* is correctly calculated. The wide interval is to be expected given that only one student tested positive in our asymptomatic cohort. We acknowledge in the discussion the limited value of this sensitivity value. We therefore combined the two cohorts of symptomatic and asymptomatic for the overall sensitivity (94.3%; 95% CI 87.2-97.5%) and specificity values (95.9%; 95% CI 92.4-97.8%).

Table 2 could be improved, for example, place 3 columns indicating detection method, positive, and negative. Transfer results of NPS into a row.
Answer: The data in Table 2 regarding sensitivities and sensitivities of SalivaDirect when compared to NPS are presented in the same format as presented in several publications (Skolimowska *et al*., 2020; Braz-Silva *et al*., 2020; Mahmoud *et al*., 2021; Pasomsub *et al*., 2021 etc) and we think that consistency allows for the easiest comparison of various tests for the readers.

Figure 2 in the Y-axis named as "Sensitivity" correct to "Sensitivity (%). In the Figure´s legend, instead of "Sensitivity (in%) ..." correct to "Percentage of sensitivity ..."
Answer: The suggested changes have been made to figure 2 and associated legend.

Discussion

Discuss what it may imply that by testing saliva this does not meet the established requirements (smoking, drinking fluids, etc.).

Answer: Smoking, drinking any liquids, food, nasal sprays, tooth brushing and/or mouth washing might affect the quality of the saliva sample and/or the validity of the saliva testing. For example, the use of mouth wash was shown to reduce the viral load in saliva samples (Seneviratne *et al*., 2021) and therefore using mouth wash prior to providing a saliva sample should be avoided. Presence of food, mucus and residues such as those from brushing teeth or smoking can decrease the quality of the samples and prove their handling more difficult due to particles presence in the saliva. A sentence about the effects of these activities on saliva testing has now been added to the method section.

It should be compared to currently used methods for rapid detection showing over 90% sensitivity. Why use SalivaDirect and not those?

Answer: We thank the reviewer for this comment. In the general context, it has been well established that rapid antigen testing have a high sensitivity (over 90%) in case of high viral load/low Ct values (although antigen approaches were not tested in parallel in our cohorts). For example, Van der Moeren and co-authors showed that BD Veritor System for Rapid Detection of SARS-CoV-2 has an overall sensitivity of 78.9% and reaching 93% for samples with Cts lower than 30 (Van der Moeren N, *et al.* PLoS One. 2021. PMID: 33983971). In another study, Fernandez-Montero reported a sensitivity of Roche SARS-CoV-2 Rapid Antigen Test of 71.43%, which increases to 93.75% when Cts were lower than 25 (Fernandez-Montero *et al*., EClinicalMedicine. 2021 Jul;37:100954. doi: 10.1016/j.eclinm.2021.100954, PMID: 34127960). In our hands the sensitivity of saliva testing compared to NPS was maintained for high Cts – it was 100% for Cts in NPS lower than 30, and, as reported in our manuscript, 94.3% overall. But most importantly, the rapid antigen tests currently available still required a nasopharyngeal swab (often self-administered in case of asymptomatic screening programmes) which is widely perceived as uncomfortable and linked to coughing, sneezing, headache which can be a barrier to repeated testing (for example with younger students). Therefore, we propose PCR-based saliva testing as a valid alternative to NSP, especially when employing SalivaDirect protocol which skips the RNA extraction step (thereby saving money and time), is a relatively cheap and accurate method to detect SARS-CoV-2, especially for those individuals who will require repeated testing. Moreover, reproducible finding of PCR-based saliva testing is a prerequisite to developing and validating rapid antigen saliva tests, which so far haven't reached satisfactory diagnostic performance (Nagura-Ikeda *et al.*, J Clin Microbiol. 2020 Aug 24;58(9):e01438-20; Audigé *et al*., Microorganisms. 2021 Aug 10;9(8):1700). We have now added a sentence in the discussion section that reinforce the advantages of this approach for PCR-based SARS-CoV-2 testing.

Did the authors notice any disadvantages of using the SalivaDirect? If so, discuss it.

Answer: We found no significant disadvantage in using SalivaDirect compared to RNA extraction-based saliva testing. However we did notice that the handling of the saliva samples was more challenging than the NPS (they were more gloopy, the colour and density varied greatly among the samples). We have now mention this in the methods section.

Competing Interests: No competing interests were disclosed.

Reviewer Report 19 August 2021

Stephanie Russo Perniciaro (ID)

Department of Epidemiology of Microbial Diseases, Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT, USA

This paper describes and contextualizes the results of a study comparing nasopharyngeal swab samples for SARS-CoV-2 detection with saliva samples for SARS-CoV-2 detection. The authors enrolled a symptomatic cohort and an asymptomatic cohort, and observed high concordance between nasopharyngeal swabs and saliva samples. Out of ~300 total samples, 14 were discordant. The sensitivity and specificity of saliva testing with the SalivaDirect protocol were high, similar to other studies of the implementation of this low-cost protocol.

The authors' analysis is thorough and appropriate for the data. Having only one person with a positive test in one of the two study cohort populations makes full generalizability of the results difficult, but the authors address this and contextualize it appropriately.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Epidemiology, infectious diseases, respiratory infections

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.